HEPATIC MICROSOME STUDIES ARE INSUFFICIENT TO CHARACTERIZE IN VIVO HEPATIC METABOLIC CLEARANCE AND METABOLIC DRUG-DRUG INTERACTIONS: STUDIES OF DIGOXIN METABOLISM IN PRIMARY RAT HEPATOCYTES VERSUS MICROSOMES
- 1 November 2004
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 32 (11) , 1311-1316
- https://doi.org/10.1124/dmd.32.11.1311
Abstract
The effects of hepatic uptake and efflux transporters on metabolism of digoxin were examined in isolated rat hepatocytes versus microsomes. The metabolic clearance estimated from microsomes was 4.59 ± 0.69 ml/min/kg. However, the metabolic clearance estimated from hepatocytes was 15.9 ± 3.0 ml/min/kg. The former did not correlate with in vivo clearance (12.9 ml/min/kg) for digoxin. Rifampin (an organic anion-transporting peptide 2 inhibitor) or GG918 [GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide)] (a potent P-glycoprotein inhibitor) were used to estimate effects of uptake or efflux transporters on digoxin metabolism. Whereas both inhibitors exerted minimal effects on metabolism in microsomes, rifampin and GG918 significantly decreased and increased digoxin metabolism in hepatocytes, respectively. Concentration-time course studies further demonstrated that, compared with the area under the curve (AUC) of control (15.6 ± 0.1 μM · min), an increase of AUC (20.1 ± 0.5 μM · min, p < 0.005) was observed when digoxin was coincubated with rifampin and a decrease of AUC (14.1 ± 0.1 μM · min, p < 0.01) when GG918 was also present. Digoxin primary metabolite concentrations changed directionally in an inverse manner with parent drug concentrations, as would be expected. These results strongly suggest that the hepatic uptake and efflux transporters that are found in hepatocytes, but not in microsomes, modulate intracellular concentration of digoxin and thus affect metabolism. We conclude that the interplay of transporters and enzymes must be considered in defining the intrinsic metabolic clearance of the liver and in evaluating potential drug-drug interactions.Keywords
This publication has 34 references indexed in Scilit:
- CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and MidazolamThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Transporter-Enzyme Interactions: Implications for Predicting Drug-Drug Interactions from In Vitro DataCurrent Drug Metabolism, 2003
- In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion ModelThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Phenomenology and Scientific ProgressCancer Biology & Therapy, 2002
- Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4The Journal of Pharmacology and Experimental Therapeutics, 2002
- Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6Journal of Biological Chemistry, 2001
- Characterizing the Expression of CYP3A4 and Efflux Transporters (P-gp, MRP1, and MRP2) in CYP3A4-Transfected Caco-2 Cells After Induction with Sodium Butyrate and the Phorbol Ester 12-O-Tetradecanoylphorbol-13-AcetatePharmaceutical Research, 2001
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and manXenobiotica, 1999
- Digitalis ToxicityAnnual Review of Medicine, 1985